^
Association details:
| Biomarker: | TP53 mutation + Chr del(17p) |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Jaypirca (pirtobrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting
Published date:
12/07/2020
Excerpt:
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company...today announced clinical data from the LOXO-305 global Phase 1/2 BRUIN clinical trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)...In the 28 patients with a 17p deletion, TP53 mutation, or both, the ORR was 79% (22/28)...
